Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.

Nagati V, Tenugu S, Salazar M, Tripathi MK

Open source

DOI
10.1016/j.drudis.2026.104788
Published
2026 Sep
Container
Drug discovery today
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104788,
  title = {Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.},
  author = {Nagati V and Tenugu S and Salazar M and Tripathi MK},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104788},
  url = {https://doi.org/10.1016/j.drudis.2026.104788}
}

RIS

TY  - JOUR
TI  - Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.
AU  - Nagati V
AU  - Tenugu S
AU  - Salazar M
AU  - Tripathi MK
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104788
UR  - https://doi.org/10.1016/j.drudis.2026.104788
ER  - 

APA

V, N., S, T., M, S., & MK, T. (2026). Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104788

Source records